Excerpt from the equity research report: Having already achieved proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers in low concentrations by counting single molecules, Prolight’s first objective is now to pioneer the Point-of-Care (POC) troponin market. Next steps involve prototype development and IVDR certification before launch in 2026. Despite inherent uncertainties in revenue, unit and cost estimates, we forecast a partner-driven rollout to a 30% peak market penetration by 2034 (10m troponin tests), which together with the potential for POC-testing of biomarkers BNP and D-Dimer supports a fair value of SEK 1.1 -1.2 per share, while other clinical areas add considerable further potential on top.

Read the full report here https://www.emergers.se/prolight_a/